GlassScriptPhysician profile
Sashidhar Movva
NPI 1265486252
$4,646.98
in general payments reported to CMS, 2019-2025
37 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Neuromusculoskeletal Medicine & Omm provider received nationally (typical 2025 total: $119).
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $311 · 2021: $567 · 2022: $1,449 · 2023: $1,005 · 2024: $556 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $889.79 | 2019-2024 | |
| Biogen, INC. | $491.50 | 2019-2023 | Vumerity |
| Neurelis, INC. | $456.81 | 2020-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $367.91 | 2019-2022 | |
| Abbvie INC. | $333.93 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $320.88 | 2019-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $228.54 | 2022-2023 | Xcopri |
| Ucb, INC. | $173.51 | 2019-2023 | Briviact |
| Lilly USA, LLC | $151.99 | 2019-2023 | Amyvid, Reyvow, Emgality |
| Amgen INC. | $115.29 | 2019-2024 | Uplizna |
| Celgene Corporation | $114.14 | 2021-2023 | Zeposia |
| Avion Pharmaceuticals | $111.04 | 2022-2023 | Dhivy |
| Eisai INC. | $107.51 | 2022-2023 | |
| Argenx US, INC. | $100.27 | 2022-2024 | Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $70.16 | 2023-2024 | Aptiom |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $59.73 | 2022 | |
| Medtronic, INC. | $58.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $48.64 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $41.28 | 2019-2023 | Austedo |
| E.R. Squibb & Sons, L.L.C. | $36.10 | 2020-2022 | |
| Banner Life Sciences, LLC | $35.81 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $34.77 | 2022-2025 | Crexont |
| Emd Serono, INC. | $27.53 | 2019-2021 | |
| Lundbeck LLC | $27.51 | 2025 | Vyepti |
| Horizon Therapeutics Plc | $26.35 | 2022 | |
| Pfizer INC. | $23.63 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.39 | 2022 | |
| Allergan, INC. | $21.70 | 2019 | |
| Ge Healthcare | $21.44 | 2019 | |
| Mdd US Operations, LLC | $19.70 | 2019 | |
| Aucta Pharmaceuticals, INC. | $19.54 | 2025 | Motpoly Xr |
| Genzyme Corporation | $18.62 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.71 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.94 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.62 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.36 | 2021 | |
| Life Molecular Imaging LTD | $10.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sashidhar Movva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.